6.74
前日終値:
$5.62
開ける:
$5.6
24時間の取引高:
3.89M
Relative Volume:
1.62
時価総額:
$370.36M
収益:
$3.64M
当期純損益:
$-87.37M
株価収益率:
-1.6399
EPS:
-4.11
ネットキャッシュフロー:
$-86.46M
1週間 パフォーマンス:
+10.86%
1か月 パフォーマンス:
+43.10%
6か月 パフォーマンス:
+16.41%
1年 パフォーマンス:
+200.89%
Verastem Inc Stock (VSTM) Company Profile
VSTM を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
VSTM
Verastem Inc
|
6.74 | 314.31M | 3.64M | -87.37M | -86.46M | -4.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-10 | 開始されました | Jefferies | Buy |
2025-03-24 | 繰り返されました | H.C. Wainwright | Buy |
2024-12-31 | 繰り返されました | BTIG Research | Buy |
2024-09-30 | 開始されました | Guggenheim | Buy |
2023-11-21 | 再開されました | BTIG Research | Buy |
2023-09-27 | 開始されました | B. Riley Securities | Buy |
2023-06-15 | アップグレード | Mizuho | Neutral → Buy |
2022-09-07 | 再開されました | Alliance Global Partners | Buy |
2022-04-29 | 再開されました | Cantor Fitzgerald | Overweight |
2022-04-14 | 開始されました | RBC Capital Mkts | Outperform |
2022-03-09 | 開始されました | Truist | Buy |
2021-07-01 | 開始されました | Alliance Global Partners | Buy |
2021-05-24 | アップグレード | BTIG Research | Neutral → Buy |
2019-06-20 | ダウングレード | BTIG Research | Buy → Neutral |
2019-05-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2018-07-13 | 開始されました | BTIG Research | Buy |
2018-05-02 | 開始されました | Seaport Global Securities | Buy |
2018-03-08 | 開始されました | B. Riley FBR, Inc. | Buy |
2017-09-07 | 繰り返されました | H.C. Wainwright | Buy |
2017-04-13 | 開始されました | Oppenheimer | Outperform |
2017-03-24 | 繰り返されました | H.C. Wainwright | Buy |
2015-09-29 | ダウングレード | Cantor Fitzgerald | Buy → Hold |
2015-09-29 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2015-09-29 | ダウングレード | Jefferies | Buy → Hold |
2015-09-29 | ダウングレード | Raymond James | Strong Buy → Outperform |
2015-09-28 | ダウングレード | Mizuho | Buy → Neutral |
2015-09-28 | ダウングレード | ROTH Capital | Buy → Neutral |
2015-09-09 | 開始されました | Raymond James | Strong Buy |
2015-05-12 | 繰り返されました | UBS | Buy |
2015-04-08 | 開始されました | H.C. Wainwright | Buy |
2015-01-23 | 繰り返されました | ROTH Capital | Buy |
2014-07-08 | 再開されました | Oppenheimer | Perform |
2014-02-11 | 開始されました | Mizuho | Buy |
すべてを表示
Verastem Inc (VSTM) 最新ニュース
Verastem (VSTM.O) Surges 19.9% on KDJ Golden Cross and Mysterious Order Flow - AInvest
Verastem Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Verastem (VSTM.O) Surges 19.9%: What’s Behind the Sharp Intraday Move? - AInvest
Using Python tools to backtest Verastem Inc. strategiesAI Trend Detection for Entry Timing - Newser
What makes Verastem Inc. stock price move sharplyMassive ROI Stock Selections - thegnnews.com
Verastem's (VSTM) Breakthrough in KRAS-Driven Cancers and Commercialization Momentum - AInvest
Transcript : Verastem, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Verastem stock climbs on Q2 beat (VSTM:NASDAQ) - Seeking Alpha
Verastem’s Promising Phase 3 Study in Ovarian Cancer: A Potential Game-Changer? - TipRanks
RBC Raises Price Target on Verastem to $13 From $12, Keeps Outperform, Speculative Risk - MarketScreener
Verastem Inc files for mixed shelf offering of up to $300 millionSEC filing - MarketScreener
Earnings call transcript: Verastem Q2 2025 sees revenue growth and FDA approval - Investing.com
Verastem’s Promising Market Expansion and Financial Health Drive Buy Rating - TipRanks
Verastem: Q2 Earnings Snapshot - Connecticut Post
Verastem Q2 2025 Earnings Call Transcript - MarketBeat
Verastem Inc (VSTM) Q2 2025 Earnings Call Highlights: FDA Approval and Strong Launch Drive ... By GuruFocus - Investing.com Canada
Verastem Oncology’s Q2 2025 Financial and Business Highlights - TipRanks
Verastem Inc (VSTM) Q2 2025 Earnings Call Highlights: FDA Approval and Strong Launch Drive Positive Momentum - GuruFocus
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - BioSpace
Verastem 2025 Q2 Earnings Deepened Losses Amid Product Launch - AInvest
Verastem Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Custom strategy builders for tracking Verastem Inc.Free Short Term Buy List With Stop Protection - Newser
Verastem Oncology Gambles On Cancer Drug Launch Despite Deepening Losses - Finimize
Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Verastem's Q2 2025 Earnings and Pipeline Progress: A Deep Dive into R&D Momentum and Long-Term Value Creation - AInvest
Biopharma firm Verastem Oncology Q2 net loss widens - MarketScreener
Verastem reports Q2 EPS (39c) vs. (31c) last year - TipRanks
Verastem CEO Paterson sells $7,738 in shares By Investing.com - Investing.com South Africa
Verastem CEO Paterson sells $7,738 in shares - Investing.com
Will Verastem Inc. continue its uptrendIntelligent Trade Forecast With AI Analytics - Newser
Intrinsic Value of Verastem Inc. Stock: Is It Undervalued or OvervaluedTechnical Trend Forecast for Investors - Newser
Best data tools to analyze Verastem Inc. stockTrading Watchlist with Real Time Filters - Newser
Visual trend scoring systems applied to Verastem Inc.Free Pattern Alert With ROI Driven Strategy - Newser
Leading vs lagging indicators on Verastem Inc. performanceFree News Based Entry Opportunity Alerts - Newser
Verastem VSTM Q2 2025 Earnings Preview Upside Potential on Strong Revenue Growth - AInvest
Jefferies Financial Group Inc. Makes New $1.63 Million Investment in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Does Verastem Inc. stock perform well during market downturnsUnlock powerful market trend analysis - Jammu Links News
What markets is Verastem Inc. expanding into Is TROO stock a good long term investment option - Jammu Links News
How strong is Verastem Inc. company’s balance sheetHigh-yield market plays - Jammu Links News
Is Verastem Inc. stock overvalued or undervaluedInvest confidently with advanced analysis tools - Jammu Links News
How does Verastem Inc. compare to its industry peersAchieve breakthrough gains with expert advice - Jammu Links News
Should I hold or sell Verastem Inc. stock in 2025Maximize gains with expert analysis - Jammu Links News
What is Verastem Inc. company’s growth strategyUnstoppable profit momentum - Jammu Links News
What institutional investors are buying Verastem Inc. stockBuild a diversified portfolio for risk mitigation - Jammu Links News
What drives Verastem Inc. stock priceOutperformance with explosive growth - Jammu Links News
What analysts say about Verastem Inc. stockFree Consultation - Jammu Links News
When is Verastem Inc. stock expected to show significant growthMarket-crushing stock picks - Jammu Links News
Verastem, Inc. (NASDAQ:VSTM) Sees Large Growth in Short Interest - Defense World
Why Verastem Inc. stock attracts strong analyst attentionBuy Signal Based on Chart Analysis Confirmed - beatles.ru
Is Verastem Inc. reversing from oversold territoryWeekly Signal Report with Trend Summary - Newser
Verastem Inc (VSTM) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):